From the American Academy of Ophthalmology
News from the FSO
From the American Academy of Ophthalmology
The U.S. Food and Drug Administration has approved Lucentis (ranibizumab injection) for the treatment of diabetic macular edema. The drug’s safety and effectiveness to treat DME were established in two clinical studies that showed a 34 to 45 percent improvement in patients treated monthly with 0.3 mg of Lucentis over a two-year period. Ophthalmologists should check with their Medicare carriers to determine coverage for Lucentis to treat DME.
From the American Academy of Ophthalmology
From the American Academy of Ophthalmology
From the American Academy of Ophthalmology
From the American Academy of Ophthalmology
Another special FSO member benefit allows you special access to download slides and recordings from the Masters in Ophthalmology 2012 Annual Meeting. Please click here to access the presentations. You will be prompted to login using your FSO username and password at the top right hand side of the page. If you cannot remember your community username or password, please contact Colleen Filbert at cfilbert@mdeye.org or you may call 904-998-0819.
From the American Academy of Ophthalmology
Physicians have an additional year, until Oct. 14, 2014, to transition from the ICD-9 coding system to ICD-10. The U.S. Department of Health and Human Services is delaying the mandatory transition in part because of the number of federal compliance burdens that physician practices face, including requirements of the Medicare electronic health record incentive program and upcoming penalties for not participating in the Physician Quality Reporting System.
From the American Academy of Ophthalmology
From the American Academy of Ophthalmology